These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18729348)

  • 1. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues.
    Yamamoto M; Horie R; Takeiri M; Kozawa I; Umezawa K
    J Med Chem; 2008 Sep; 51(18):5780-8. PubMed ID: 18729348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.
    Watanabe M; Nakashima M; Togano T; Higashihara M; Watanabe T; Umezawa K; Horie R
    Biochem Biophys Res Commun; 2008 Nov; 376(2):310-4. PubMed ID: 18782563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual intramolecular N-->O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine.
    Kozawa I; Kato K; Teruya T; Suenaga K; Umezawa K
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5380-2. PubMed ID: 19679468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular design and biological activities of NF-kappaB inhibitors.
    Umezawa K; Chaicharoenpong C
    Mol Cells; 2002 Oct; 14(2):163-7. PubMed ID: 12442886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
    Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
    Umezawa K
    Biomed Pharmacother; 2011 Jul; 65(4):252-9. PubMed ID: 21723080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
    Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
    Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
    Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K; Kikuchi E; Kosugi M; Horiguchi Y; Matsumoto K; Kanai K; Suzuki E; Miyajima A; Nakagawa K; Tachibana M; Umezawa K; Oya M
    Urology; 2010 Apr; 75(4):805-12. PubMed ID: 20156648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
    Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF-kappaB activation by blocking specific cysteine residues of IkappaB kinase beta and p65/RelA.
    Ha KH; Byun MS; Choi J; Jeong J; Lee KJ; Jue DM
    Biochemistry; 2009 Aug; 48(30):7271-8. PubMed ID: 19591457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
    Suzuki E; Sugiyama C; Umezawa K
    Biomed Pharmacother; 2009 Jun; 63(5):351-8. PubMed ID: 18635336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
    Suzuki E; Ninomiya Y; Umezawa K
    Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
    Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2.
    Niitsu Y; Hakamata M; Goto Y; Higashi T; Shoji M; Sugai T; Umezawa K
    Org Biomol Chem; 2011 Jun; 9(12):4635-41. PubMed ID: 21541373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
    Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
    Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
    J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.